% | $
Quotes you view appear here for quick access.

Taro Pharmaceutical Industries Ltd. Message Board

  • moydegem moydegem Jun 7, 2013 12:37 AM Flag

    Taro hits the trifecta with fundamentals, chap price, and catalyst

    the following is from bet.fool
    ...Shareholders rejected a $39.50/share offer last year that grossly undervalued the company. Even at $58/share the market values Taro at 5.74 times EV/EBITDA. Considering recent comparable acquisitions, Taro remains underpriced by 53% relative to the minimum acquisition price, and nearly threefold relative to the median.

    Which stock has the best prescription for profits?

    Given the recent pullback and the strong psychological anchor of the already rejected offer, it seems unlikely that Taro will fall much further. The present price appears to be an attractive entry point, and a buyer today can count on improving business fundamentals or immediate price appreciation if Sun increases its offer.
    Taro hits the trifecta with very attractive fundamentals, a cheap share price relative to its growth, and a catalyst for higher prices on the horizon. Thus, it seems likely that an investment in the company will provide excellent returns moving forward.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
143.15+1.30(+0.92%)Nov 25 4:03 PMEST